226 related articles for article (PubMed ID: 16399090)
1. Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization.
De Luca L; Orlandi C; Udelson JE; Fedele F; Gheorghiade M
Am J Cardiol; 2005 Dec; 96(12A):24L-33L. PubMed ID: 16399090
[TBL] [Abstract][Full Text] [Related]
2. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
Veeraveedu PT; Palaniyandi SS; Yamaguchi K; Komai Y; Thandavarayan RA; Sukumaran V; Watanabe K
Drug Discov Today; 2010 Oct; 15(19-20):826-41. PubMed ID: 20708094
[TBL] [Abstract][Full Text] [Related]
3. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
[TBL] [Abstract][Full Text] [Related]
4. Vasopressin and vasopressin receptor antagonists in heart failure.
Oghlakian G; Klapholz M
Cardiol Rev; 2009; 17(1):10-5. PubMed ID: 19092365
[TBL] [Abstract][Full Text] [Related]
5. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure.
LeJemtel TH; Serrano C
Int J Cardiol; 2007 Aug; 120(1):1-9. PubMed ID: 17346825
[TBL] [Abstract][Full Text] [Related]
6. Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism.
Rosner MH; Ronco C
Congest Heart Fail; 2010 Jul; 16 Suppl 1():S7-14. PubMed ID: 20653716
[TBL] [Abstract][Full Text] [Related]
7. Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.
Schwarz ER; Sanghi P
Expert Rev Cardiovasc Ther; 2006 Jan; 4(1):17-23. PubMed ID: 16375624
[TBL] [Abstract][Full Text] [Related]
8. Conivaptan: promise of treatment in heart failure.
Hoque MZ; Arumugham P; Huda N; Verma N; Afiniwala M; Karia DH
Expert Opin Pharmacother; 2009 Sep; 10(13):2161-9. PubMed ID: 19663609
[TBL] [Abstract][Full Text] [Related]
9. Vasopressin receptor antagonists: potential indications and clinical results.
Arai Y; Fujimori A; Sudoh K; Sasamata M
Curr Opin Pharmacol; 2007 Apr; 7(2):124-9. PubMed ID: 17292670
[TBL] [Abstract][Full Text] [Related]
10. Hyponatremia and arginine vasopressin dysregulation: mechanisms, clinical consequences, and management.
Miller M
J Am Geriatr Soc; 2006 Feb; 54(2):345-53. PubMed ID: 16460390
[TBL] [Abstract][Full Text] [Related]
11. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.
Goldsmith SR
Am J Cardiol; 2005 May; 95(9A):14B-23B. PubMed ID: 15847853
[TBL] [Abstract][Full Text] [Related]
12. Hyponatremia in heart failure: the role of arginine vasopressin and diuretics.
Rosner MH
Cardiovasc Drugs Ther; 2009 Aug; 23(4):307-15. PubMed ID: 19554441
[TBL] [Abstract][Full Text] [Related]
13. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
14. Vasopressin antagonism: a future treatment option in heart failure.
Sanghi P; Uretsky BF; Schwarz ER
Eur Heart J; 2005 Mar; 26(6):538-43. PubMed ID: 15695526
[TBL] [Abstract][Full Text] [Related]
15. Vasopressin-receptor antagonists.
Hoorn EJ; Zietse R
Future Cardiol; 2010 Jul; 6(4):523-34. PubMed ID: 20608824
[TBL] [Abstract][Full Text] [Related]
16. Hyponatremia: current treatment strategies and the role of vasopressin antagonists.
Cawley MJ
Ann Pharmacother; 2007 May; 41(5):840-50. PubMed ID: 17405824
[TBL] [Abstract][Full Text] [Related]
17. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
[TBL] [Abstract][Full Text] [Related]
18. Vasopressin: a new target for the treatment of heart failure.
Lee CR; Watkins ML; Patterson JH; Gattis W; O'connor CM; Gheorghiade M; Adams KF
Am Heart J; 2003 Jul; 146(1):9-18. PubMed ID: 12851603
[TBL] [Abstract][Full Text] [Related]
19. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism.
Rai A; Whaley-Connell A; McFarlane S; Sowers JR
Am J Nephrol; 2006; 26(6):579-89. PubMed ID: 17170524
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms, risks, and new treatment options for hyponatremia.
Ghali JK
Cardiology; 2008; 111(3):147-57. PubMed ID: 18434717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
